ReviewMolecular carcinogenesis2020
Tumor immune microenvironment in head and neck cancers.
Review in Molecular carcinogenesis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 1 synthesis or guideline pooled it, 173 citations in OpenAlex.
- A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC.BMC cancer · 2023Pooled it
- Article
- Single nucleus RNA profiling reveals potential therapeutic vulnerabilities in sinonasal carcinomas.NPJ precision oncology · 2026Article
- Hydrogels in head and neck cancer: Innovations and translational advances in research and therapy.Biomaterials · 2026Review
- Driving progress in recurrent and metastatic head and neck cancer: the NRG Oncology perspective.Journal of the National Cancer Institute · 2026Review
- Multifactorial effects of LGALS1 blockade sensitize tumors to immune checkpoint inhibitor.Experimental hematology & oncology · 2026Article
- Prognostic Impact and Clinicopathological Significance of TIM-3 and LAG-3 Expressions in Laryngeal Squamous Cell Carcinoma.Laryngoscope investigative otolaryngology · 2026Article
- Targeting the NKG2D axis in head and neck squamous cell carcinoma: from molecular insights to clinical applications.Cancer cell international · 2026Review
- NIR-II biomimetic nanoplatform optogenetic CD274 editing of HNSCC immunogenicity for enhanced photoimmunotherapy.Materials today. Bio · 2026Article
- LILRB1 Is a Prognostic-Related Biomarker Correlated With Immune Infiltration in Head-Neck Squamous Cell Carcinoma.Cancer medicine · 2026Article
- Analysis of the efficacy of camrelizumab/cetuximab neoadjuvant therapy in patients with loco-regionally advanced laryngeal and hypopharyngeal cancer and the prognostic value of NLR/SII.World journal of surgical oncology · 2026Article
- Role of the Super-Enhancer Component Bromodomain Protein 4 in the Radiation Response of Human Head and Neck Squamous Cell Carcinoma Cells.Current issues in molecular biology · 2026Article
- Next Generation Calcium Nanomaterials: Disrupting Tumor CaInternational journal of nanomedicine · 2026Review
- Characterizing the Head and Neck Cancer Microenvironment: Implications for Immunotherapy and Prognosis.Advances in experimental medicine and biology · 2026Review
- Multi-omics analysis identifies CLDN10 as a B-cell-associated prognostic biomarker in HPV-negative head and neck squamous cell carcinoma.Frontiers in cell and developmental biology · 2026Article
- Nano-Engineered Cetuximab-Copper Complexes for Targeted Drug Delivery in Head and Neck Cancer.Current drug delivery · 2026Article
- Single-cell RNA sequencing reveals hypoxia-associated stress response signatures in the immune and stromal microenvironment of laryngeal squamous cell carcinoma.Frontiers in immunology · 2026Article
- Development of a Prognostic Nomogram Model and Establishment of a Risk Stratification System Based on the Naples Prognostic Score for Patients with Oropharyngeal Squamous Cell Carcinoma Who Have Undergone Radical Surgery.Journal of inflammation research · 2026Article
- Red-complex bacteria: immunological background leading to the development of head and neck cancers.Frontiers in immunology · 2026Review
- Ovatodiolide overcomes cisplatin resistance in head and neck cancer by disrupting a novel oncogenic signature and cancer-associated fibroblast activation.Journal of dental sciences · 2026Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Head and neck cancers are a heterogeneous group of tumors that are highly aggressive and collectively represent the sixth most common cancer worldwide. Ninety percent of head and neck cancers are squamous cell carcinomas (HNSCCs). The tumor microenvironment (TME) of HNSCCs consists of many different subsets of cells that infiltrate the tumors and interact with the tumor cells or with each other through various networks. Both innate and adaptive immune cells play a crucial role in mediating immune surveillance and controlling tumor growth. Here, we discuss the different subsets of immune cells and how they contribute to an immunosuppressive TME of HNSCCs. We also briefly summarize recent advances in immunotherapeutic approaches for HNSCC treatment. A better understanding of the multiple factors that play pivotal roles in HNSCC tumorigenesis and tumor progression may help define novel targets to develop more effective immunotherapies for patients with HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.